Mostrar el registro sencillo

dc.contributor.authorRenuncio-García, Mónica
dc.contributor.authorCalvo del Río, Vanesa
dc.contributor.authorBenavides-Villanueva, Fabricio
dc.contributor.authorAl Fazazi, Salma
dc.contributor.authorRodríguez-Vidriales, María
dc.contributor.authorEscagedo-Cagigas, Clara
dc.contributor.authorMartín Penagos, Luis
dc.contributor.authorIrure Ventura, Juan
dc.contributor.authorLópez Hoyos, Marcos 
dc.contributor.authorBlanco Alonso, Ricardo 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-04-23T18:07:40Z
dc.date.available2024-04-23T18:07:40Z
dc.date.issued2024
dc.identifier.issn0257-277X
dc.identifier.issn1559-0755
dc.identifier.urihttps://hdl.handle.net/10902/32669
dc.description.abstractANCA-associated vasculitis (AAV) comprises a group of necrotizing vasculitis that mainly affects small- and medium-sized vessels. Serum anti-neutrophil cytoplasmic antibodies (ANCA), mainly anti-myeloperoxidase (anti-MPO) and anti-proteinase 3 (anti-PR3), levels may correlate to severity, prognosis, and recurrence of the disease. A retrospective analysis of 101 patients with MPO-positive and 54 PR3-positive vasculitis was performed, using laboratory established cut-off value, measured by chemiluminescence. Furthermore, data of renal disease and pulmonary involvement were collected at vasculitis diagnosis, as well as the progress, requiring dialysis, transplant, or mortality. For anti-MPO antibodies with a diagnosis of vasculitis (n=77), an area under the curve (AUC) was calculated (AUC=0.8084), and a cut-off point of 41.5 IU/ml was determined. There were significant differences in anti-MPO levels between patients with renal or pulmonary dysfunction (n=65) versus those without them (n=36) (p=0.0003), and a cut-off threshold of 60 IU/ml was established. For anti-PR3 antibodies with a diagnosis of vasculitis (n=44), an area under the curve (AUC) was calculated (AUC=0.7318), and a cut-off point of 20.5 IU/ml was determined. Significant differences in anti-PR3 levels were observed between those patients with renal or pulmonary dysfunction (n=30) and those without them (n=24) (p=0.0048), and a cut-off threshold of 41.5 IU/ml was established. No significant differences between those patients who had a worse disease progression and those who did not were found for anti-MPO and anti-PR3. Anti-MPO and anti-PR3 levels at the moment of vasculitis diagnosis are related with disease severity but not with disease outcome or vasculitis recurrence.es_ES
dc.description.sponsorshipFunding: Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.es_ES
dc.format.extent6 p.es_ES
dc.language.isoenges_ES
dc.publisherSpringer International Publishinges_ES
dc.rights© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceImmunologic Research, 2024, 72, 128-133es_ES
dc.subject.otherANCA-associated vasculitises_ES
dc.subject.otherAntibody titeres_ES
dc.subject.otherSeverityes_ES
dc.subject.otherPrognosises_ES
dc.subject.otherAnti-MPO and anti-proteinase 3es_ES
dc.subject.otherMicroscopic polyangiitises_ES
dc.subject.otherGranulomatosis with polyangiitises_ES
dc.subject.otherEosinophilic granulomatosis with polyangiitises_ES
dc.subject.otherSingle-organ ANCA vasculitises_ES
dc.titleANCA detection with solid phase chemiluminescence assay: diagnostic and severity association in vasculitises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1007/s12026-023-09422-zes_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1007/s12026-023-09422-z
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.Excepto si se señala otra cosa, la licencia del ítem se describe como © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.